CompletedNot Applicable

Comparison of Deferasirox and Desferoxamine in Patients of β-Thalassemia Major With Iron Overload

Pakistan142 participantsStarted 2023-01-01

Plain-language summary

This study was planned to compare deferasirox and desferrioxamine in terms of mean serum ferritin levels in patients of β-thalassemia major having Iron overload. Choosing an effective iron chelator is crucial to increasing iron chelation therapy compliance. Not much local data exists in Pakistan comparing the effectiveness of deferasirox (DFX) and desferrioxamine (DFO), so, this study would be helpful in providing baseline data and formulating new protocols for iron chelation therapy, in which DFX may be a useful oral alternative to parenteral DFO.

Who can participate

Age range2 Years – 15 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of β-thalassemia major (as per medical record or confirmed by hemoglobin electrophoresis) * Iron overload (serum ferritin level above 1000 µg/L) Exclusion Criteria: * Patients with other transfusion-dependent anemias * Thalassemia major with cardiomyopathy or arrhythmia. * Chronic renal failure * Chronic liver disease (ALT \>200 IU) * Hhypersensitivity to deferasirox or desferrioxamine * Patients already on combined chelation therapy

What they're measuring

Mean Serum Ferritin Levels

Timeframe: 6 months

Trial details

NCT IDNCT06468423

SponsorRESnTEC, Institute of Research

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-09-30

View on ClinicalTrials.gov More Pateints of β-thalassemia Major With Iron Overload trials